Levast et al., 2019 - Google Patents
2579. Impact on the Gut Microbiota of the Prolonged Antimicrobial Therapy in Patients with Bone and Joint Infection (BJI): Results From the OSIRIS Prospective Study …Levast et al., 2019
View PDF- Document ID
- 17897053662507944346
- Author
- Levast B
- Batailler C
- Pouderoux C
- Boucihna L
- Lustig S
- Boutoille D
- Dauchy F
- Zeller V
- Senneville E
- Maynard M
- Laurent F
- Ferry T
- Publication year
- Publication venue
- Open Forum Infectious Diseases
External Links
Snippet
Background There is growing interest about the deleterious impact of antibiotics on loss of gut symbiosis, called dysbiosis. As patients with BJI require antibiotics usually during 6 to 12 weeks, it is of interest to determine whether dysbiosis is frequent in this population, and if it …
- 210000001035 Gastrointestinal Tract 0 title abstract description 12
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oka et al. | Microbial-based and microbial-targeted therapies for inflammatory bowel diseases | |
| AU2021258070A1 (en) | Intestinal microbiota and GVHD | |
| Morowitz et al. | The human microbiome and surgical disease | |
| Byarugaba et al. | Multi-drug resistance in commensal bacteria of food of animal origin in Uganda | |
| US11723935B2 (en) | Methods and compositions for treating and diagnosing pancreatic cancers | |
| MX2013012607A (en) | Bacillus bacteria for use in treating and preventing infection in aquatic animals. | |
| Zhou et al. | Antibiotic administration routes and oral exposure to antibiotic resistant bacteria as key drivers for gut microbiota disruption and resistome in poultry | |
| US12076350B2 (en) | Fecal microbiota composition for use in reducing treatment-induced inflammation | |
| RU2460778C1 (en) | Method for producing autoprobiotic of enterocuccus faecium being representative of indigenic host intestinal microflora | |
| AU2018209227A1 (en) | Autologous fecal sample for use in the treatment of microbial dysbiosis | |
| de la Torre et al. | Multidrug resistance in Escherichia coli carrying integrons isolated from a pig farm with moderate antibiotic use | |
| WO2019149859A1 (en) | Gut commensal bacteria for treatment of human colorectal cancer | |
| Zhang et al. | In vitro evaluation of probiotic properties of lactic acid bacteria isolated from the vagina of yak (Bos grunniens) | |
| Levast et al. | 2579. Impact on the Gut Microbiota of the Prolonged Antimicrobial Therapy in Patients with Bone and Joint Infection (BJI): Results From the OSIRIS Prospective Study in France | |
| Alnezary et al. | 2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis. | |
| Sethi et al. | 2582. The Association Between Dietary Fiber and Diet and Gut Colonization with Clostridium difficile. | |
| You et al. | Lactobacillus acidophilus novel strain, MJCD175, as a potential probiotic for oral health in dogs | |
| WO2019157566A1 (en) | Compositions and methods for promoting gut health | |
| Agga et al. | Tetracycline-and macrolide-resistant enterococcus species isolated from a Mink Farm in the United States | |
| US20200281991A1 (en) | Methods and compositions for treating disorders related to a gut dysbiosis | |
| Ahmad et al. | 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms. | |
| Gonzales-Luna et al. | 2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations | |
| Park et al. | 2578. Narrow-Spectrum Antibiotic Treatment of Clostridium difficile Infection Improves Preservation of Intestinal Metabolic Profile. | |
| US20200085885A1 (en) | Probiotic compositions and methods | |
| Seong et al. | 2584. Effects of Fecal Microbiota Transplantation for Decolonizing Multidrug-Resistant Organism |